GSK secures expanded approval for Jemperli from FDA: A major advancement in endometrial cancer treatment

GSK secures expanded approval for Jemperli from FDA: A major advancement in endometrial cancer treatment

In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab) to include all adult patients with primary advanced or recurrent endometrial cancer. This expanded approval now encompasses patients with mismatch repair proficient (MMRp) or microsatellite stable (MSS) tumours, which account for the majority of endometrial cancer cases. […]

GSK’s Blenrep shows significant efficacy in DREAMM-7 trial in multiple myeloma

GSK’s Blenrep shows significant efficacy in DREAMM-7 trial in multiple myeloma

GSK plc has unveiled promising results from the DREAMM-7 phase III trial, which highlights a notable advancement in the treatment of relapsed or refractory multiple myeloma. The trial compared the effectiveness of Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BorDex) against the standard of care daratumumab plus BorDex combination. The findings, set to […]

GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma

GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma

GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple myeloma. This pivotal trial demonstrated a statistically significant progression-free survival (PFS) benefit for Blenrep combined with bortezomib and dexamethasone (BorDex) against the daratumumab plus BorDex regimen. Trial Details and Efficacy […]

GSK secures full Jemperli FDA approval for endometrial cancer treatment

GSK secures full Jemperli FDA approval for endometrial cancer treatment

Biopharma company GSK has secured the full approval of the US Food and Drug Administration (FDA) for its Jemperli (dostarlimab-gxly) drug for recurrent or advanced mismatch repair-deficient endometrial cancer. Jemperli is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has advanced or after a prior platinum-containing […]